FDA's Perspectives on Cross- Contamination in CMO Facilities, Considering High Risk Products
|
|
- Lesley Woods
- 6 years ago
- Views:
Transcription
1 FDA's Perspectives on Cross- Contamination in CMO Facilities, Considering High Risk Products Bo Chi, Ph.D. Biotech Manufacturing Assessment Branch DGMPA/OMPQ/OC/CDER 1
2 Outline Regulatory framework Regulatory expectations for crosscontamination control Case studies 2
3 Unique challenges of CMOs Multiple and diverse products High risk biotech products (antibody-drug-conjugates, toxins, etc.) Risks of cross-contamination 3
4 Risk and science based manufacturing Examples of regulations and guidance intend to encourage risk and science based manufacturing: ICH Q8, Q9, Q10 21 CFR (c) ICH Q CFR (e) 4
5 Regulation and guidance 21CFR211.42(c) There shall be separate or defined areas or such other control systems for the firm s operations as are necessary to prevent contamination or mix-ups during the course of the following procedures 5
6 Regulation and guidance 21CFR211.42(d) Operations relating to the manufacture, processing, and packing of penicillin shall be performed in facilities separate from those used for other drug products for human use. 6
7 Regulation and guidance ICH Q7 4.4 Containment Dedicated production areas should be employed in the production of highly sensitizing materials, such as penicillins or cephalosporins. Dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is involved unless validated inactivation and/or cleaning procedures are established and maintained. 7
8 Regulation and guidance 21CFR600.11(e)(3) Work with sporeforming microorganisms Manufacturing processes using sporeforming microorganisms conducted in multiproduct manufacturing site must be performed under appropriate controls to prevent contamination of other products and areas within the site. Prevention of spore contamination can be achieved by a separate dedicated building or by using process containment if manufacturing is conducted in a multiproduct manufacturing building. 8
9 Regulation and guidance 21CFR600.11(e)(4) Live vaccine processing (i)(a) Using a dedicated manufacturing area. (ii) If manufacturing is conducted in a multiproduct manufacturing building or area, using procedural controls, and where necessary, process containment. Process containment is deemed to be necessary unless procedural controls are sufficient to prevent cross contamination of other products and other manufacturing areas within the building. 9
10 FDA expectations for facilities manufacture high risk products The decision to manufacture high risk products in dedicated or shared facilities should be approached holistically and factors considered should be documented in a risk management plan. Risk management plan is evaluated during the inspection and/or submission review processes. 10
11 Risk Management ICH Q9, Quality Risk Management Risk assessment for cross-contamination Identify, analyze, and evaluate the risks Risk control and mitigation to acceptable level for cross-contamination Determine facility, procedure, and process controls necessary to minimize risks of crosscontamination Use dedicated facility or areas if risks cannot be mitigated to acceptable level 11
12 Cross-contamination routes (1) Mix-up Accidental use of wrong materials or contaminated equipment Overlapping process flows and transit routes, common storage areas Mitigations: facility design, procedures (e.g., adequate changeover procedures, labeling) and controls Retention Product residue carryover Inadequate equipment cleaning Mitigations: adequate cleaning validation, cleaning verification of shared equipment between campaigns ISPE Volume 7, Risk-based manufacture of pharmaceutical products,
13 Cross-contamination routes(2) Mechanical transfer Contaminant residue moving from one process or area to another Mitigations: procedure (e.g., gown control, equipment wipe down), closed process, and facility control (e.g., adequate flow of equipment and personnel) Airborne transfer Powder available in air and contacts product and equipment Mitigations: containment, closed process, segregated areas, and facility control (e.g., adequate pressure differential and airlocks) ISPE Volume 7, Risk-based manufacture of pharmaceutical products,
14 Regulatory expectations for Crosscontamination control Facility Design Process containment Equipment Procedure controls 14
15 Facility design Facility layout designed to allow for adequate material, personnel, product, equipment flow to minimize potential cross-contamination through crossover points. Segregation Spatial segregation for different operations Separate air handling units (AHU) to control mixing of air from different areas Use airlocks and pressure differential for product protection and process containment 15
16 Process containment Use closed systems whenever possible Closed product transfer Closed sampling Contain high risk open operations (e.g., in an isolator) Spore-forming production microorganisms Toxin purification process Weighing and dissolving the drug component of antibody-drug-conjugates (ADCs) 16
17 Equipment Equipment Dedicated or disposable equipment Shared product contact equipment Process equipment Shared non-product contact equipment Isolator (weighing and dissolving drug) CIP and COP systems 17
18 Equipment decontamination Decontaminate spores and neutralize/inactivate/solubilize hazardous compounds on equipment using validated method prior to equipment cleaning More effective cleaning Reduces risk of cross-contamination through shared glass washers and CIP systems 18
19 Equipment cleaning validation Cleaning validation acceptance criteria for product residues should be scientifically determined for adequate cross-contamination control 1/1000 th of the lowest clinical dose or 10 ppm may not be appropriate for potent/toxic products Acceptable Daily Exposure (ADE) considered Toxicologically derived A dose that is unlikely to cause an adverse effect if an individual is exposed, by any route, at or below this dose every day for a lifetime. (ISPE Vol 7, 2010) 19
20 Equipment Cleaning Validation Analytical method for product residue Sensitivity Dedicated or disposable equipment should be used if the cleaning acceptance criteria cannot be met We recommend dedicating equipment for carcinogenic/ mutagenic products 20
21 Procedure controls Campaign-based manufacturing Adequate flow of equipment, products, raw materials, and waste to prevent cross-contamination through product crossover points Procedure controls to prevent mix-ups Gowning and flow of personnel Personnel training Spill control procedures Effective facility cleaning and disinfection 21
22 Changeover Dedicated equipment, raw materials, consumables, product, waste, and documents for the previous product are removed Cleaning verification of shared product-contact equipment during changeover 22
23 Changeover (Continued) Verification of no residual sporeforming production microorganisms in shared equipment during changeover (if equipment is not sterilized) Effective decontamination of the shared area Environmental monitoring specific for the spore-forming production organisms is performed for the shared area 23
24 Case studies 24
25 Case Study #1 Contract drug substance manufacture site for antibody-drug conjugates Multi-product facility Campaign-based manufacturing Conjugates highly potent small molecule drugs to monoclonal antibodies 25
26 Case Study #1 (Continued) No documented risk management plan available The highly potent small molecule drugs (powder) are weighed and dissolved in an isolator. The facility could not provide justifications for the cleaning validation acceptance criteria for the small molecule drug residue for the isolator. 26
27 483 Observation The risk assessment to justify the containment strategy and controls that are necessary to prevent cross-contamination of - - bulk drug substance by another potent product is inadequate. Specifically, a. there was no written risk assessment evaluating the cross-contamination of Product X by the highly potent small molecule intermediate and the potent bulk drug substance of another product manufactured at the same area. b. the acceptance criteria for cleaning validation of shared non-product contact surfaces for highly potent small molecule intermediates are not justified..the isolator is used to weigh and dissolve small molecule intermediate for Product X during its bulk drug substance campaign. 27
28 Case Study #2 Contract manufacturer for aseptically filled drug products Multiproduct filling line for toxic/potent products The product of interest (Product A) shares a product-contact hold tank with a carcinogenic/mutagenic product (Product B) 28
29 Case Study #2 (Continued) Shared sterile hold tank: Cleaning validation acceptance criteria for product residue limits were determined based on 1/1000th of the lowest clinical dose No cleaning verification conducted during product changeover No cleaning verification conducted after the initial validation three years ago Concern of safety and purity of some clinical and market launch lots of Product A 29
30 Resolving of potential crosscontamination issues FDA OND Pharmacology/Toxicology team was consulted for the evaluation of ADE for Product B Cleaning validation acceptance criteria established based on the ADE were agreed Multiple information requests and teleconferences with the contract facility CMO was requested by FDA to inform the sponsor of the submission 30
31 Resolving of issues (Continued) Cleaning verification of Product B was conducted with three runs and results met the agreed product residue limits The initial cleaning validation data met the new product residue limits Short-term remedy: cleaning verification after changeover Long-term remedy: dedicate a hold tank to Product A The submission was approved 31
32 Lessons learned The sponsor should have reviewed CMO s risk management plan for crosscontamination control Risk mitigation strategies for crosscontamination should have been adequately implemented Practice should have been improved when introducing a new product Better communication between the sponsor and the CMO 32
33 Case Study #3 Contract drug product manufacture site Submission for introducing a potent toxin to a filling line approved for a monoclonal antibody 33
34 Case Study #3 (Continued) Quality risk management plan Follows ICH Q9 Evaluated risks from mix-up, retention, mechanical transfer, and airborne transfer (ISPE Risk-MaPP Baseline Guide Volume 7) 34
35 Case Study #3 (Continued) Drug substance pre-formulated Extremely diluted toxin 35
36 Case Study #3 (Continued) Process containment Facility High air exchange rate Dedicated return air system Use of airlocks Closed operations whenever possible Closed sampling and transfer process of the bulk 36
37 Case Study #3 (Continued) Equipment Dedicated or disposable productcontact equipment Toxin is inactivated by the cleaning agent Equipment is autoclaved prior to use 37
38 Case Study #3 (Continued) Procedure controls Campaign dedicated suites Gowning Controls and disposable gowning Redundant procedure controls to prevent mix-ups Operator training Spill control procedures Rooms are decontaminated and sanitized 38
39 Summary Multiproduct CMOs for high risk products are expected to identify cross-contamination risks and implement controls necessary to minimize these risks FDA reviews the risk management plans during inspections and/or submission reviews 39
40 Summary Adequate quality agreement should be in place between the CMO and sponsor Oversight of the CMO is the responsibility of the sponsor Both the CMO and sponsor are responsible in ensuring that the manufacturing process in place has adequate cross-contamination control Guidance for Industry, Contract Manufacturing Arrangements for Drugs: Quality Agreements, 2013 draft guidance 40
41 Acknowledgements Patricia Hughes, Ph.D. Reyes Candauchacon, Ph.D. Lakshmi Narasimhan, Ph.D. Kalavati Suvarna, Ph.D. 41
Product Protection Control Strategies for Non-Sterile Drug Substance Manufacturing
Protection Control Strategies for Non-Sterile Drug Substance Manufacturing Michael Hendershot, Research Scientist Technical Services / Manufacturing Sciences Eli Lilly & Company Contents Purpose of a Protection
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationCleaning and Cleaning Validation of API Plant and Equipment
Regulatory Basis: FDA Quality Systems Regulations Reference: FDA CFR - Code of Federal Regulations Title 21 1 Purpose The purpose of this guideline is: To define the requirements for cleaning plant and
More informationISPE S GUIDES AND HOW THEY APPLY TO CLEANING AND CLEANING VALIDATION
ISPE S GUIDES AND HOW THEY APPLY TO CLEANING AND CLEANING VALIDATION Stephanie A. Wilkins, PE ISPE NORDIC CLEANING VALIDATION CONFERENCE 20 April 2016 Objectives > ISPE s Risk-MaPP Guide and its impact
More informationRegulatory Considerations on. Office of Biotechnology Products
Regulatory Considerations on Multiproduct t Facilities for Biotechnology Products Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA 2011 CASSS CMC Strategy
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationFacility and Operational Issues for Cord Blood Banks: FDA Draft Guidance
Facility and Operational Issues for Cord Blood Banks: FDA Draft Guidance Mary Malarkey, Director Office of Compliance and Biologics Quality ISCT 7 th Annual Somatic Cell Therapy Symposium, September 26-28,
More informationSetting Limits in Shared Facilities
Setting Limits in Shared Facilities The New Scientific Approach 27 h September 2012 Sarah O Meara, Ph.D. Non-clinical Assessor & SWP Delegate, Irish Medicines Board Slide 1 Principles of Pharmacology and
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationBasic Principles of GMP. Sanitation and Hygiene
Basic Principles of GMP Sanitation and Hygiene Module 3 Slide 1 of 26 Objectives Review measures to ensure good sanitation in: premises equipment processes To review measures to ensure good personnel hygiene
More informationGMP considerations when designing an API plant. Presented by Cameron Roberts, Senior Engineer 4 July, 2016
GMP considerations when designing an API plant Presented by Cameron Roberts, Senior Engineer 4 July, 2016 Introduction API manufacturing is too broad a topic to cover all scenarios so I will draw from
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationCROSS-CONTAMINATION IN SHARED FACILITIES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 043-1 1 July 2018 AIDE-MEMOIRE CROSS-CONTAMINATION IN SHARED FACILITIES PIC/S July 2018 Reproduction prohibited for
More informationJournal of Atoms and Molecules
Review article Journal of Atoms and Molecules An International Online Journal ISSN 2277 1247 CLEANING VALIDATION IN PHARMACEUTICAL INDUSTRIES Abhishek Raj Senior R&D Officer, Quest Pharmaceuticals Pvt.
More informationHealth Products and Food Branch Inspectorate Graham Spry Building, 3 rd Floor 250 Lanark Avenue Address Locator # 2003D OTTAWA, Ontario K1A 0K9 January 4, 2008 07-128997-672 TO: ALL INTERESTED PARTIES
More informationDesign and Construction of Biocontainment Laboratories
Design and Construction of Biocontainment Laboratories Commissioning and Validation Benjamin MABILE Director Global Validation, GSK Biologicals GSK Biologicals Context - Vaccines Key elements of the Validation
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationMicrobiological Consideration for Non-Sterile Pharmaceutical
May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control
More informationCLEANING VALIDATION WITH RISK ASSESSMENT
CLEANING VALIDATION WITH RISK ASSESSMENT Bangkok, Thailand July 26 2017 Jairaj (Jai) Mehta, Consultant, Promoting the Quality of Medicines 2016. ALL RIGHTS RESERVED. Presentation Outline: Cleaning Validation
More informationHVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction
HVAC and Risk Management RACI Meeting 7 th December 2011 Dr Stephen Firmer Asia Pacific Consultants Pty Ltd Agenda Context Project Management Design Construction Qualification Routine Control /Potential
More informationDriving Value through Innovation in Biotech Manufacturing. Agenda
Driving Value through Innovation in Biotech Manufacturing Jorg Thommes, PhD Senior Vice President Operations Technology and Innovation Biogen 7 October 2015 Agenda Biopharma Legacy, Trends, & Challenges
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 15 July 2010 European Commission Enterprise and Industry Directorate General Consumer Goods, Pharmaceuticals B-1049 Brussels
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationContract Manufacturing Services for Pre-filled Syringes
Contract Manufacturing Services for Pre-filled Syringes From Standard Solutions to Complex Products Stefan Czvitkovich, PhD Director Product Partnering Sterile Pharmaceuticals Central Europe CPhI woldwide
More informationCompliance Trends Paula Katz
Compliance Trends Paula Katz Director, Manufacturing Quality Guidance and Policy Staff Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research India Pharmaceutical
More informationRE: Draft Annex 2: Manufacture of Biological Medicinal Products for Human Use
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 14 March 2008 European Commission Enterprise and Industry Directorate-General B-1049 Brussels Belgium BY EMAIL TO entr-gmp@ec.ec.europa.eu
More informationSupersedes Division Name Revision No. 0 Export Division Page No. 1 of 9
Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This
More informationCleaning validation of cleanrooms and preparation equipments
Cleaning validation of cleanrooms and preparation equipments Dr Farshid SADEGHIPOUR Head of production Central Pharmacy, Geneva University Hospitals EAHP Foundation Seminar: Patient Safety; More About
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More information3M Drug Delivery Systems. April 26, 2011
3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation
More informationMitigating Cross-Contamination in Shared Production Facilities Using Risk-Based Cleaning Validation Methods: Considerations and Case Study
Mitigating Cross-Contamination in Shared Production Facilities Using Risk-Based Cleaning Validation Methods: Considerations and Case Study December 2018 Contact Information Promoting the Quality of Medicines
More informationCGMP for Phase 1 INDs
CGMP for Phase 1 INDs Laurie P. Norwood Deputy Director Division of Manufacturing and Product Quality Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research 1 Overview
More informationAntibody Drug Conjugates - Introduction to a new EBE initiative EBE Satellite Session Paris - May 9, 2016
Antibody Drug Conjugates - Introduction to a new EBE initiative EBE Satellite Session Paris - May 9, 2016 Presented by Fred Jacobson (Genentech) on behalf of the ADC task force How it got started... May
More informationCleaning / Cleaning Validation Update on toxicological approach
Cleaning / Cleaning Validation Update on toxicological approach Paul Sexton, Sarah O Meara, Denise Coakley GMP Conference 12th November 2014 Content Section I - Introduction Section II Toxicological Tool
More informationWorld Journal of Pharmaceutical Research SJIF Impact Factor 5.990
SJIF Impact Factor 5.990 Volume 4, Issue 9, 421-436. Review Article ISSN 2277 7105 CLEANING VALIDATION OF PHARMACEUTICAL DOSAGE FORMS Gupta Mamta* and Bharkatiya Meenakshi B.N. Institute of Pharmaceutical
More informationCOMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,
More informationBiopharmaceutical Multi-Product Facilities: the Challenges and the Solutions. Frank Hallinan EBE Biopharmaceutical Manufacturing & CMC Conference
Biopharmaceutical Multi-Product Facilities: the Challenges and the Solutions. Frank Hallinan EBE Biopharmaceutical Manufacturing & CMC Conference Barcelona, March 21, 2011 Agenda: The Past The Business
More informationHigh Potency Drugs from Molecule to Market
High Potency Drugs from Molecule to Market David O Connell, Director Pharmaceutical Development, PCI Pharma Services High Potency Drugs from Molecule to Market PCI Pharma Services has invested in state-of-the-art
More informationTHE USE OF NON-PHARMACEUTICAL GRADE SUBSTANCES IN THE UA ANIMAL CARE & USE PROGRAM
THE USE OF NON-PHARMACEUTICAL GRADE SUBSTANCES IN THE UA ANIMAL CARE & USE PROGRAM POLICY: This policy provides a definitive position on the use of non-pharmaceutical grade substances in the UA animal
More informationOverview of Cleaning Validation in Pharmaceutical Industry
Overview of Cleaning Validation in Pharmaceutical Industry 1 Pankaj P Chandra Treya, 2 Dr. D N Jhade 1 Research Scholar, SSSUTMS, Sehore 2 Research Guide, SSSUTMS, Sehore Abstract Manufacturing of Pharmaceutical
More informationImpact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut
Impact of EU GMPs on Australian GMP Trevor Schoerie PharmOut Part I Basic Requirements for Medicinal Products Current TGA Version, 7 years out of date TGA are actively and publically talking about PE009-0813
More informationDRAFT OECD GLP ADVISORY DOCUMENT NO. 19 ON THE MANAGEMENT, CHARACTERISATION AND USE OF TEST ITEMS PREAMBLE
DRAFT OECD GLP ADVISORY DOCUMENT NO. 19 ON THE MANAGEMENT, CHARACTERISATION AND USE OF TEST ITEMS PREAMBLE 1. This guidance provides clarity for test facilities on the expectations of national Good Laboratory
More informationINSPECTION OF BIOTECHNOLOGY MANUFACTURES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 024-2 25 September 2007 AIDE-MEMOIRES INSPECTION OF BIOTECHNOLOGY MANUFACTURES PIC/S September 2007 Reproduction prohibited
More informationTHE GMP HANDBOOK ANNEXES. g o o d m a n u fac t u r i n g p r ac t i c e. quality systems for the pharmaceutical industry.
THE GMP HANDBOOK g o o d m a n u fac t u r i n g p r ac t i c e quality systems for the pharmaceutical industry Ke y2 C om pl ia nc e AB by Anna Lundén ANNEXES Key2Compliance AB Annexes - Content Annexes
More informationCombination Products at US FDA
Multimodal Therapies for Brain Disorders: Session II Regulatory and Reimbursement Considerations Combination Products at US FDA Patricia Y. Love, MD, MBA Deputy Director Office of Combination Products,
More informationManual: 038. Cleaning and Cleaning Validation of API Plant and Equipment
Title: Cleaning and Cleaning Validation of API Plant and Equipment Manual Number: 38 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Manual: 38 Cleaning and
More informationEngineering & Validation Training Program
MAPAQ Engineering & Validation Training Program PBE, Pharma Bio Expert Inc PBE-Expert Inc CANADA PBE is a Training Company with Agreement CPMT #0059104 PBE, Training Company Agreement CPMT #0059104 2 MAPAQ
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationGood manufacturing practices guide for drug products GUI-0001
Good manufacturing practices guide for drug products GUI-0001 February 28, 2018 Good manufacturing practices guide for drug products (GUI-0001) Author: Health Canada Date issued: February 28, 2018 Implementation
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationBenefits of a Risk-Based Cleaning Validation Approach during New Product Introduction
Benefits of a Risk-Based Cleaning Validation Approach during New Product Introduction Jenna Carlson, Sr. Technical Manager 2009, Genentech / Proprietary information Please do not copy, distribute or use
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationCross Contamination Within a Pharmaceutical Manufacturing Plant. Belinda Whalan Operations QC Laboratory Manager, Pfizer
Cross Contamination Within a Pharmaceutical Manufacturing Plant Belinda Whalan Operations QC Laboratory Manager, Pfizer Contamination The undesired introduction of impurities of a chemical or microbiological
More informationLABORATORY COMPLIANCE
1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationCOMPANY PROFILE. Dishman offers innovation, security of supply and value for money. Dishman Group. Research EARLY STAGE API. Preclinical.
COMPANY PROFILE Dishman is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and services. Dishman improves its customers businesses by providing
More informationThe Cleaning Validation Process
The Cleaning Validation Process The Scope of Cleaning Validation The Cleaning Validation Sequence Prerequisites Cleaning Validation Strategy, Plan, and Policy Sampling Recovery Studies Analytical Method
More informationComparison of Guidelines of Indian GMP with WHO GMP
Comparison of Guidelines of Indian GMP with WHO GMP By Dr. Uma Vasireddy, M.Pharm,Ph.D.., Professor and Principal, KIPS,Wgl, INDIA 1 Outline of Presentation Introductory Elements Section wise Comparison
More informationValidation Needs for Sterilization by Aseptic Filtration
Validation Needs for Sterilization by Aseptic Filtration DCVMN Workshop, Hyderabad, 4-8 April 2016 Ramesh Raju Associate Director - Provantage Validation Services Overview Key Regulatory and Industry guidelines
More informationICH Q11 Questions & Answers Selection & Justification of Starting Materials. Q11 Implementation Working Group 22 May 2018
IC Q11 Questions & Answers Selection & Justification of. Training Material Q11 Implementation Working Group 22 May 2018 International Council for armonisation of Technical Requirements for Pharmaceuticals
More informationAppropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products
Date: April 23, 2012 Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Key Messages Importation quality control testing for pharmaceutical, biological/biotechnology
More informationCurrent version 13 October 2016
Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order
More informationRegula'on of Contracep'ves
Regula'on of Contracep'ves VETERINARY DRUG DEVELOPMENT: REGULATION OF STERILANTS AND CONTRACEPTIVES David M. Petrick, VMD, JD The Delta Consortium Regulatory Consulting Limited Copyright July, 2018 Veterinary
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More informationEuropean Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009
European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationTest item OECD guideline No 19
Test item OECD guideline No 19 Advisory Document of the Working Group on Good Laboratory Practice on the Management, Characterisation and Use of Test Items sophie.svensson@swedac.se Agenda Background Definitions
More informationEquipment cleaning and use record
DOCUMENTATION Documentation is an essential part of the quality assurance system and, as such, should be related to all aspects of GMP. Its aim is to define the specifications for all materials and the
More informationSynopsis: FDA Process Validation Guidance
Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.
More informationAdministrative Files; STN /0 - Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine, MenHibrix
DEPARTMENT OF HEALTH & HUMAN SERVICES US Food & Drug Administration Center for Biologics Evaluation & Research Office of Compliance & Biologics Quality Division of Manufacturing & Product Quality MEMORANDUM
More informationICH Q11 Questions & Answers Selection & Justification of Starting Materials. Step 4 August Implementation Working Group
ICH Q11 Questions & Answers Selection & Justification of. Step 4 August 2017 Implementation Working Group International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human
More informationISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE September/October 2008, Vol. 28 No. 5 This executive summary provides an overview of the second edition of the ISPE Baseline Guide:
More informationCurrent Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)
Current Trends in Sterile Manufacturing by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS) Executive Summary Drug developers go to great lengths to assure that their
More informationDrug Good Manufacturing Practices Inspections
Drug Good Manufacturing Practices Inspections New England District Investigations Branch Parenteral Drug Association New England Chapter May 17, 2006 DRUG MANUFACTURING INSPECTIONS Inspections Include:
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationAdvancements on implementation of single use technology in vaccine manufacturing
Advancements on implementation of single use technology in vaccine manufacturing October 25 th, 2013 DCVMN Meeting Rio de Janeiro, Brazil Outline Overview of single use products Applications of single
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015
Ref. Ares(2015)3808922-15/09/2015 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, [date] This document is for consultation until 11
More informationGeorge Bernstein, Ph.D. Double Dragon Consulting Inc.
THE AMERICAN ASSOCIATION OF HOMEOPATHIC PHARMACISTS George Bernstein, Ph.D. Double Dragon Consulting Inc. 1. Introduction 2. Background 3. Validation Master Plan 4. Tips for Success 5. What Do I Need to
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationQ8 Pharmaceutical Development
Q8 Pharmaceutical Development For questions regarding this draft document contact (CDER) Ajaz Hussain at 301-594-2847 or (CBER) Christopher Joneckis at 301-435-5681. This draft guidance, when finalized,
More informationRegulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective
Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective ASQ509 Biomed/Biotech SIG 2/1/18 Xiaobin Victor Lu Division of Cellular and Gene Therapies Office of Tissues
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationResource management with respect to buildings and facilities in pharmaceutical and biotech industry - An overview of regulatory guidelines
Review Article Resource management with respect to buildings and facilities in pharmaceutical and biotech industry - An overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT In the
More informationRecent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca
Recent Developments & Future Directions in the Production of Monoclonal Antibodies Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Forecast sales by molecule type ($m), 2006 12 600,000 Pharmaceuticals
More informationCleaning Procedures. These guidelines are intended for Bulk Pharmaceutical Chemicals but almost every word applies to Drug Products
CLEANING DEVELOPMENT Cleaning Procedures as the FDA See It These guidelines are intended for Bulk Pharmaceutical Chemicals but almost every word applies to Drug Products BPC CLEANING (& Drug Products)
More informationGPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationRegulation of Microbiota- Based Products
Regulation of Microbiota- Based Products LCDR Matthew Steele, PhD Team Leader, Regulatory Review Branch 1 Division of Vaccines and Related Products Applications CBER/OVRR My presentation is an informal
More informationMicrodose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry
Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationWhite Paper. Risk Management in Environmental Monitoring: Should you be spotting it sooner?
White Paper Risk Management in Environmental Monitoring: Should you be spotting it sooner? Executive Overview Quality Risk Management is a comparatively new approach in the pharmaceutical manufacturing
More informationHealth Products and Food Branch Inspectorate
OUR MANDATE: To promote good nutrition and informed use of drugs, food, medical devices and natural health products, and to maximize the safety and efficacy of drugs, food, natural health products, medical
More informationGuidance for Industry
Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center
More informationCBER Expectations Regarding Contract Manufacturing
CBER Expectations Regarding Contract Manufacturing LCDR Qiao Bobo, Ph.D. FDA/CBER/OCBQ/DMPQ CASSS CMC Strategy Forum Summer 2014 Outline 2 Types of Cooperative Manufacturing Arrangements CBER Expectations
More informationS9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create
More informationENVIRONMENTAL MANAGEMENT GUIDE FOR SMALL LABORATORIES
United States Office of the EPA 233-B-00-001 Environmental Protection Administrator May 2000 Agency (2131) ENVIRONMENTAL MANAGEMENT GUIDE FOR SMALL LABORATORIES 3.5 Biologically Active Substances and Wastes
More informationRegulation of Active Pharmaceutical Ingredients (API)
Regulation of Active Pharmaceutical Ingredients (API) Stephan Rönninger Head External Affairs Europe, International Quality June 21, 2013 SINDUSFARMA / ANVISA / FIP-IPS Conference, Brasilia Agenda Regulations
More information